Physician profile
Jun Hee Lee
NPI 1891795522
$4,040.39
in general payments reported to CMS, 2019-2025
29 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $209 · 2021: $131 · 2022: $778 · 2023: $607 · 2024: $674 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $555.32 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $521.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.74 | 2019-2025 | Jardiance |
| Abbott Laboratories | $367.47 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals Lp | $363.74 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $280.85 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $278.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $160.65 | 2019-2020 | |
| Boston Scientific Corporation | $128.77 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company Ltd. | $102.07 | 2022 | |
| Optinose US, INC. | $90.44 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $88.97 | 2019-2022 | |
| Allergan, INC. | $77.33 | 2019-2022 | |
| Dexcom, INC. | $60.34 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $56.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.38 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $53.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.87 | 2025 | |
| Medtronic, INC. | $39.82 | 2022-2025 | Inceptiv |
| Amgen INC. | $35.79 | 2019-2024 | Prolia, Evenity |
| Neurocrine Biosciences, INC. | $34.54 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $31.87 | 2022-2023 | Prehevbrio |
| Genentech USA, INC. | $30.39 | 2019-2021 | |
| Abbvie INC. | $28.79 | 2019 | |
| Gilead Sciences, INC. | $21.09 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.49 | 2023 | Quviviq |
| Seqirus USA INC | $15.77 | 2025 | Fluad, Flucelvax |
| Insulet Corporation | $13.12 | 2022 | |
| Amarin Pharma, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.